Associated-risk determinants for anthroponotic cutaneous leishmaniasis treated with meglumine antimoniate: A cohort study in Iran.
Adolescent
Adult
Aged
Aged, 80 and over
Antiprotozoal Agents
/ therapeutic use
Child
Child, Preschool
Cohort Studies
Cryotherapy
/ methods
Female
Humans
Infant
Infant, Newborn
Iran
/ epidemiology
Leishmania tropica
/ isolation & purification
Leishmaniasis, Cutaneous
/ drug therapy
Male
Meglumine Antimoniate
/ therapeutic use
Middle Aged
Risk Factors
Treatment Failure
Young Adult
Journal
PLoS neglected tropical diseases
ISSN: 1935-2735
Titre abrégé: PLoS Negl Trop Dis
Pays: United States
ID NLM: 101291488
Informations de publication
Date de publication:
06 2019
06 2019
Historique:
received:
22
05
2018
accepted:
29
04
2019
revised:
24
06
2019
pubmed:
13
6
2019
medline:
28
11
2019
entrez:
13
6
2019
Statut:
epublish
Résumé
The control of cutaneous leishmaniasis (CL) is facilitated by knowledge of factors associated with the treatment failures in endemic countries. The aim of this evaluation was to identify the potential risk determinants which might affect the significance of demographic and clinical characteristics for the patients with anthroponotic CL (ACL) and the outcome of meglumine antimoniate (MA) (Glucantime) treatment. This current was executed as a cohort spanning over a period of 5 years which centered in southeastern part of Iran. Altogether, 2,422 participants were evaluated and 1,391 eligible volunteer patients with ACL caused by Leishmania tropica were included. Overall, 1,116 (80.2%) patients received MA intraleisionally (IL), once a week for 12 weeks along with biweekly cryotherapy, while 275 (19.8%) patients received MA alone (20 mg/kg/day for 3 weeks) (intramuscular, IM). The treatment failure rate in ACL patients was 11% using IL combined with cryotherapy plus IM alone, whilst 9% and 18.5% by IL along with cryotherapy or IM alone, respectively. Multivariate logistic regression model predicted 5 major associated-risk determinants including male (odds ratio (OR) = 1.54, confidence interval (CI) = 1.079-2.22, p = 0.018), lesion on face (OR = 1.574, CI = 1.075-2.303, p = 0.02), multiple lesions (OR = 1.446, CI = 1.008-2.075, p = 0.045), poor treatment adherence (OR = 2.041, CI = 1.204-3.46, p = 0.008) and disease duration > 4 months (OR = 2.739, CI = 1.906-3.936, p≤0.001). The present study is the original and largest cohort of ACL patients who treated with MA. A comprehensive intervention and coordinated action by the health authorities and policy-makers are crucial to make sure that patients strictly follow medical instructions. Early detection and effective therapy < 4 months following the onset of the lesion is critical for successful treatment of the patients. Since a significant number of patients are still refractory to MA, reducing man-vector exposure and development of new effective alternative drugs are essential measures against ACL due to L. tropica.
Sections du résumé
BACKGROUND
The control of cutaneous leishmaniasis (CL) is facilitated by knowledge of factors associated with the treatment failures in endemic countries. The aim of this evaluation was to identify the potential risk determinants which might affect the significance of demographic and clinical characteristics for the patients with anthroponotic CL (ACL) and the outcome of meglumine antimoniate (MA) (Glucantime) treatment.
METHODOLOGY/PRINCIPAL FINDINGS
This current was executed as a cohort spanning over a period of 5 years which centered in southeastern part of Iran. Altogether, 2,422 participants were evaluated and 1,391 eligible volunteer patients with ACL caused by Leishmania tropica were included. Overall, 1,116 (80.2%) patients received MA intraleisionally (IL), once a week for 12 weeks along with biweekly cryotherapy, while 275 (19.8%) patients received MA alone (20 mg/kg/day for 3 weeks) (intramuscular, IM). The treatment failure rate in ACL patients was 11% using IL combined with cryotherapy plus IM alone, whilst 9% and 18.5% by IL along with cryotherapy or IM alone, respectively. Multivariate logistic regression model predicted 5 major associated-risk determinants including male (odds ratio (OR) = 1.54, confidence interval (CI) = 1.079-2.22, p = 0.018), lesion on face (OR = 1.574, CI = 1.075-2.303, p = 0.02), multiple lesions (OR = 1.446, CI = 1.008-2.075, p = 0.045), poor treatment adherence (OR = 2.041, CI = 1.204-3.46, p = 0.008) and disease duration > 4 months (OR = 2.739, CI = 1.906-3.936, p≤0.001).
CONCLUSIONS/SIGNIFICANCE
The present study is the original and largest cohort of ACL patients who treated with MA. A comprehensive intervention and coordinated action by the health authorities and policy-makers are crucial to make sure that patients strictly follow medical instructions. Early detection and effective therapy < 4 months following the onset of the lesion is critical for successful treatment of the patients. Since a significant number of patients are still refractory to MA, reducing man-vector exposure and development of new effective alternative drugs are essential measures against ACL due to L. tropica.
Identifiants
pubmed: 31188834
doi: 10.1371/journal.pntd.0007423
pii: PNTD-D-18-00658
pmc: PMC6590833
doi:
Substances chimiques
Antiprotozoal Agents
0
Meglumine Antimoniate
75G4TW236W
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0007423Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
PLoS Negl Trop Dis. 2017 Aug 10;11(8):e0005739
pubmed: 28796782
Microb Pathog. 2018 Mar;116:124-129
pubmed: 29353004
Clin Infect Dis. 2008 Jan 15;46(2):223-31
pubmed: 18171254
Proc Biol Sci. 2018 Aug 1;285(1884):
pubmed: 30068671
Int J Infect Dis. 2018 Sep;74:109-116
pubmed: 30017946
Clin Infect Dis. 2002 Jun 15;34(12):E69-73
pubmed: 12032913
J Infect Public Health. 2013 Apr;6(2):120-4
pubmed: 23537825
PLoS One. 2012;7(5):e35671
pubmed: 22693548
Front Immunol. 2012 Oct 04;3:301
pubmed: 23060880
PLoS Negl Trop Dis. 2012;6(6):e1656
pubmed: 22720098
PLoS Negl Trop Dis. 2017 Jul 13;11(7):e0005713
pubmed: 28704369
PLoS Negl Trop Dis. 2016 May 26;10(5):e0004545
pubmed: 27227772
Trop Med Int Health. 2018 Jun;23(6):622-633
pubmed: 29709098
Int J Dermatol. 2010 May;49(5):557-61
pubmed: 20534092
PLoS Negl Trop Dis. 2010 Mar 23;4(3):e639
pubmed: 20351787
Patient Prefer Adherence. 2013 Jul 10;7:675-82
pubmed: 23874088
PLoS One. 2018 Feb 7;13(2):e0192236
pubmed: 29415078
Microb Pathog. 2019 Mar;128:162-170
pubmed: 30583021
Health Psychol. 2004 Mar;23(2):207-18
pubmed: 15008666
Biomed Res Int. 2018 Jun 6;2018:6049198
pubmed: 29984240
Int J Dermatol. 2004 Apr;43(4):281-3
pubmed: 15090013
Southeast Asian J Trop Med Public Health. 2011 May;42(3):502-8
pubmed: 21706927
Acta Dermatovenerol Croat. 2008;16(2):60-4
pubmed: 18541100
Iran J Public Health. 2015 Mar;44(3):299-307
pubmed: 25905072
Epidemiol Infect. 1995 Apr;114(2):297-318
pubmed: 7705493
J Parasitol. 2016 Oct;102(5):501-506
pubmed: 27310301
Curr Opin Infect Dis. 2015 Oct;28(5):426-37
pubmed: 26312442
Iran J Parasitol. 2017 Oct-Dec;12(4):544-553
pubmed: 29317879
PLoS One. 2014 Feb 20;9(2):e89043
pubmed: 24586494
PLoS Negl Trop Dis. 2017 Dec 14;11(12):e0006052
pubmed: 29240765
J Am Acad Dermatol. 2007 Aug;57(2):335.e1-29
pubmed: 17337090
Int J Dermatol. 2002 Aug;41(8):521-4
pubmed: 12207774
Am Fam Physician. 2004 Mar 15;69(6):1455-60
pubmed: 15053410
Int J Dermatol. 2007 Aug;46(8):848-52
pubmed: 17651170